Genflow Biosciences Plc (GB:GENF) has released an update.
Genflow Biosciences Plc, a biotech firm specializing in longevity research, has received a €395,847 grant from the Government of Wallonia to fund its Exofastrack research program. The grant will cover 80% of the program’s expenses, aiding the development of an innovative exosome therapy targeting liver fibrosis and Werner Syndrome. CEO Dr. Eric Leire expressed excitement over the grant’s potential to accelerate their pioneering work in exosome-based treatments for age-related diseases.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
